Clinical Trials Browser

OTHER × Squamous Cell Carcinoma of Head and Neck × Erlotinib Hydrochloride × Clear all

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Neoplasms, Squamous Cell

NCT00720304 2024-08-22

Erlotinib, Docetaxel, and Radiation Therapy in Stage III or Stage IV Squamous Cell Carcinoma of the Head and Neck

Phase 2 Completed

43 enrolled 16 charts

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT01064479 2024-07-16

Combination Chemotherapy With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck

Phase 2 Completed

123 enrolled 13 charts

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT01332279 2023-04-04

Everolimus, Erlotinib Hydrochloride, and Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer Previously Treated With Radiation Therapy

Phase 1 Withdrawn

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Salivary Gland Neoplasms, Tongue Neoplasms

NCT01515137 2023-03-28

Study of TARCEVA (Erlotinib) as Adjuvant Treatment for Locally Advanced Head and Neck Squamous Cell Carcinoma

Phase 1 Completed

47 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT01192815 2020-05-12

Erlotinib Hydrochloride and Radiation Therapy in Stage III-IV Squamous Cell Cancer of the Head and Neck

Phase 2 Terminated

2 enrolled 8 charts

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT00573989 2019-01-03

Intensity-Modulated Radiation Therapy, Pemetrexed, and Erlotinib in Treating Patients With Recurrent or Second Primary Head and Neck Cancer

Phase 1/2 Terminated

27 enrolled 18 charts

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT00601913 2018-07-05

Erlotinib and Surgery in Treating Patients With Head and Neck Cancer That Can Be Removed by Surgery

Phase EARLY_PHASE1 Completed

24 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT01316757 2018-02-26

Carboplatin, Paclitaxel, Cetuximab, and Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Head and Neck Squamous Cell Cancer

Phase 2 Completed

24 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Salivary Gland Neoplasms, Tongue Neoplasms

NCT00392665 2017-04-13

Bevacizumab/Tarceva and Tarceva/Sulindac in Squamous Cell Carcinoma of the Head and Neck

Phase 2 Terminated

36 enrolled 10 charts

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT00281866 2016-10-12

Erlotinib in Treating Patients With Metastatic and/or Recurrent Head and Neck Cancer

Phase 2 Completed

37 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

Clinical Trials

OSI-774/Cisplatin/Taxotere in Head & Neck Squamous Cell Cancer

Erlotinib, Docetaxel, and Radiation Therapy in Stage III or Stage IV Squamous Cell Carcinoma of the Head and Neck

Combination Chemotherapy With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck

Everolimus, Erlotinib Hydrochloride, and Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer Previously Treated With Radiation Therapy

Study of TARCEVA (Erlotinib) as Adjuvant Treatment for Locally Advanced Head and Neck Squamous Cell Carcinoma

Erlotinib Hydrochloride and Radiation Therapy in Stage III-IV Squamous Cell Cancer of the Head and Neck

Intensity-Modulated Radiation Therapy, Pemetrexed, and Erlotinib in Treating Patients With Recurrent or Second Primary Head and Neck Cancer

Erlotinib and Surgery in Treating Patients With Head and Neck Cancer That Can Be Removed by Surgery

Carboplatin, Paclitaxel, Cetuximab, and Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Head and Neck Squamous Cell Cancer

Bevacizumab/Tarceva and Tarceva/Sulindac in Squamous Cell Carcinoma of the Head and Neck

Erlotinib in Treating Patients With Metastatic and/or Recurrent Head and Neck Cancer